EXELNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends January 1
EXELIXIS, INC.
Financials through Q2 FY2026, quarter ended Jul 3, 2026Last filing: 10-Q on Aug 5, 2026
$62.68+0.45 (+0.72%)
Close on Oct 19, 2026
- Market cap
- $16.28B
- P/E (TTM)
- 19.7
- Dividend yield
- –
Exelixis statistics
Financials through Jul 3, 2026, price as of Oct 19, 2026, median of Biological Products, (No Diagnostic Substances) companies for comparison
Valuation
| Measure | Exelixis | Industry median |
|---|---|---|
| Market Cap | $15.53B | $197.05M |
| Enterprise Value | $14.69B | $106.56M |
| PE Ratio | 19.71 | 20.52 |
| PS Ratio | 6.38 | 3.93 |
| PB Ratio | 8.42 | 2.14 |
| P/TBV Ratio | 8.72 | 2.46 |
| P/FCF Ratio | 13.25 | 18.25 |
| P/OCF Ratio | 13.12 | 13.78 |
Enterprise value
| Measure | Exelixis | Industry median |
|---|---|---|
| EV / Sales | 6.03 | 2.69 |
| EV / EBITDA | 14.69 | 14.86 |
| EV / EBIT | 15.12 | 19.00 |
| EV / FCF | 12.53 | 21.02 |
Income (trailing twelve months)
| Measure | Exelixis | Industry median |
|---|---|---|
| Revenue | $2.44B | $57.94M |
| Gross Profit | $2.35B | $90.47M |
| Operating Income | $971.51M | -$21.44M |
| Net Income | $860.62M | -$22.46M |
| EBITDA | $999.81M | -$16.91M |
| EPS (Diluted) | $3.18 | -$0.83 |
Margins
| Measure | Exelixis | Industry median |
|---|---|---|
| Gross Margin | 96.5% | 52.3% |
| Operating Margin | 39.9% | -44.5% |
| Profit Margin | 35.3% | -39.2% |
| EBITDA Margin | 41.0% | -31.3% |
| FCF Margin | 48.1% | -8.85% |
Returns
| Measure | Exelixis | Industry median |
|---|---|---|
| Return on Equity (ROE) | 44.4% | -53.1% |
| Return on Assets (ROA) | 33.3% | -41.0% |
| Return on Invested Capital (ROIC) | 68.3% | -32.0% |
| Return on Capital Employed (ROCE) | 45.6% | -37.8% |
Growth
| Measure | Exelixis | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 9.23% | 6.01% |
| Net Income Growth (YoY) | 42.9% | -37.7% |
| EPS Growth (YoY) | 52.9% | -29.2% |
| FCF Growth (YoY) | 55.5% | 2.34% |
| Revenue Growth (3Y CAGR) | 12.9% | 2.25% |
| Revenue Growth (5Y CAGR) | 18.6% | 6.42% |
| EPS Growth (3Y CAGR) | 70.6% | -0.17% |
| EPS Growth (5Y CAGR) | 51.4% | 3.77% |
Balance sheet
| Measure | Exelixis | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $839.39M | $62.42M |
| Net Cash (Debt) | $839.39M | $15.68M |
| Net Cash Per Share | $3.39 | $0.65 |
| Equity (Book Value) | $1.84B | $48.79M |
| Book Value Per Share | $7.44 | $1.36 |
| Tangible Book Value | $1.78B | $23.06M |
| Working Capital | $888.90M | $75.77M |
Financial position
| Measure | Exelixis | Industry median |
|---|---|---|
| Current Ratio | 3.46 | 3.30 |
| Quick Ratio | 3.21 | 2.39 |
Cash flow (trailing twelve months)
| Measure | Exelixis | Industry median |
|---|---|---|
| Operating Cash Flow | $1.18B | -$12.35M |
| Capital Expenditures | -$10.96M | -$1.06M |
| Free Cash Flow | $1.17B | -$20.28M |
| FCF Per Share | $4.73 | -$0.41 |
Efficiency
| Measure | Exelixis | Industry median |
|---|---|---|
| Asset Turnover | 0.94 | 0.38 |
| Inventory Turnover | 3.28 | 2.67 |
| Revenue Per Employee | $2.26M | $398.96K |
| Profits Per Employee | $799.09K | -$732.08K |
| Employee Count | 1,077 | 73 |
Dividends and yields
| Measure | Exelixis | Industry median |
|---|---|---|
| Earnings Yield | 5.54% | -21.2% |
| FCF Yield | 7.55% | -7.64% |
| Buyback Yield | 7.18% | -0.58% |
| Shareholder Yield | 7.18% | 0.00% |
Shares
| Measure | Exelixis | Industry median |
|---|---|---|
| Shares Outstanding | 247,782,000 | 59,128,900 |
| Shares Change (YoY) | -6.54% | 11.1% |
| Shares Change (QoQ) | -1.90% | 0.54% |
| Float | 223,734,000 | 48,744,500 |
| Shares Held by Insiders | 9.71% | 11.8% |
| Shares Held by Institutions | 104.8% | 59.4% |
Taxes
| Measure | Exelixis | Industry median |
|---|---|---|
| Income Tax | $174.84M | $91.50K |
Scores
| Measure | Exelixis | Industry median |
|---|---|---|
| Graham Number | $23.07 | $17.36 |
| Graham Upside | -63.2% | -45.5% |
| Altman Z-Score | 16.87 | 0.10 |
| Piotroski F-Score | 7 | 4 |
| Beneish M-Score | -2.61 | -2.62 |
Calculated by StockData from Exelixis's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.